These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29614694)

  • 1. An overview of the Cure SMA membership database: Highlights of key demographic and clinical characteristics of SMA members.
    Belter L; Cook SF; Crawford TO; Jarecki J; Jones CC; Kissel JT; Schroth M; Hobby K
    J Neuromuscul Dis; 2018; 5(2):167-176. PubMed ID: 29614694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy.
    Belter L; Jarecki J; Reyna SP; Cruz R; Jones CC; Schroth M; O'Toole CM; O'Brien S; Hall SA; Johnson NB; Paradis AD
    J Neuromuscul Dis; 2021; 8(1):109-123. PubMed ID: 33104036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States.
    Lally C; Jones C; Farwell W; Reyna SP; Cook SF; Flanders WD
    Orphanet J Rare Dis; 2017 Nov; 12(1):175. PubMed ID: 29183396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinal muscular atrophy: survival pattern and functional status.
    Chung BH; Wong VC; Ip P
    Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex Difference in Spinal Muscular Atrophy Patients - are Males More Vulnerable?
    Sun J; Harrington MA; Porter B;
    J Neuromuscul Dis; 2023; 10(5):847-867. PubMed ID: 37393514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing natural history of spinal muscular atrophy type 1.
    Oskoui M; Levy G; Garland CJ; Gray JM; O'Hagen J; De Vivo DC; Kaufmann P
    Neurology; 2007 Nov; 69(20):1931-6. PubMed ID: 17998484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of muscular dystrophy and spinal muscular atrophy in Croatia: data from national and non-governmental organization registries.
    Draušnik Ž; Cerovečki I; Štefančić V; Mihel S; Stevanović R; Barišić N; Matković H; Melša M; Mirić M; Pjevač N; Benjak T
    Croat Med J; 2019 Dec; 60(6):488-493. PubMed ID: 31894913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.
    Zerres K; Rudnik-Schöneborn S; Forrest E; Lusakowska A; Borkowska J; Hausmanowa-Petrusewicz I
    J Neurol Sci; 1997 Feb; 146(1):67-72. PubMed ID: 9077498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early infantile form of spinal muscular atrophy (Werdnig-Hoffmann disease) with prolonged survival.
    Borkowska J; Rudnik-Schoneborn S; Hausmanowa-Petrusewicz I; Zerres K
    Folia Neuropathol; 2002; 40(1):19-26. PubMed ID: 12121035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients.
    Rouault F; Christie-Brown V; Broekgaarden R; Gusset N; Henderson D; Marczuk P; Schwersenz I; Bellis G; Cottet C
    Neuromuscul Disord; 2017 May; 27(5):428-438. PubMed ID: 28237437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III.
    Rudnik-Schöneborn S; Hausmanowa-Petrusewicz I; Borkowska J; Zerres K
    Eur Neurol; 2001; 45(3):174-81. PubMed ID: 11306862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autosomal recessive proximal spinal muscular atrophy in 101 sibs out of 48 families: clinical picture, influence of gender, and genetic implications.
    Rudnik-Schöneborn S; Röhrig D; Morgan G; Wirth B; Zerres K
    Am J Med Genet; 1994 May; 51(1):70-6. PubMed ID: 8030672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-reported quality of life has no correlation with functional status in children and adolescents with spinal muscular atrophy.
    de Oliveira CM; Araújo AP
    Eur J Paediatr Neurol; 2011 Jan; 15(1):36-9. PubMed ID: 20800519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hip dislocation in patients with spinal muscular atrophy.
    Sporer SM; Smith BG
    J Pediatr Orthop; 2003; 23(1):10-4. PubMed ID: 12499935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and prevalence of acromegaly in a large US health plan database.
    Burton T; Le Nestour E; Neary M; Ludlam WH
    Pituitary; 2016 Jun; 19(3):262-7. PubMed ID: 26792654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study.
    Qian Y; McGraw S; Henne J; Jarecki J; Hobby K; Yeh WS
    BMC Neurol; 2015 Oct; 15():217. PubMed ID: 26499462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community.
    Cruz R; Belter L; Wasnock M; Nazarelli A; Jarecki J
    Clin Ther; 2019 May; 41(5):943-960.e4. PubMed ID: 31056304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of 83 cases with spinal muscular atrophy in children].
    Li H; Wang HL; Shan CM
    Zhonghua Er Ke Za Zhi; 2004 Oct; 42(10):762-4. PubMed ID: 16221347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putting our best foot forward: Clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy.
    Vukovic S; McAdam L; Zlotnik-Shaul R; Amin R
    J Paediatr Child Health; 2019 Jan; 55(1):18-24. PubMed ID: 30246272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.